InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2026-02-04 | Josh Gottheimer(D-NJ05) | house | Purchase | $1,001 - $15,000 |
| 2025-12-19 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-12-18 | Julie Johnson(D-TX32) | house | Sale | $1,001 - $15,000 |
| 2025-11-18 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-11-13 | Julie Johnson(D-TX32) | house | Sale | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Sales | $65.01B+1.3% | $64.17B+6.7% | $60.12B+1.4% | $59.28B+21.7% | $48.70B |
| Cost of sales | $16.38B+7.8% | $15.19B-5.8% | $16.13B-7.4% | $17.41B+27.8% | $13.63B |
| Selling, general and administrative | $10.73B-0.8% | $10.82B+3.0% | $10.50B+4.6% | $10.04B+4.2% | $9.63B |
| Research and development | $15.79B-12.0% | $17.94B-41.2% | $30.53B+125.4% | $13.55B+10.6% | $12.24B |
| Restructuring costs | $889.0M+187.7% | $309.0M-48.4% | $599.0M+77.7% | $337.0M-49.0% | $661.0M |
| Other (income) expense, net | $151.0M+729.2% | -$24.0M-105.2% | $466.0M-69.0% | $1.50B+211.9% | -$1.34B |
| Total costs, expenses and other | $43.94B-0.7% | $44.23B-24.0% | $58.23B+35.9% | $42.84B+23.0% | $34.83B |
| Income Before Taxes | $21.07B+5.7% | $19.94B+955.4% | $1.89B-88.5% | $16.44B | — |
| Taxes on Income | $2.80B+0.0% | $2.80B+85.4% | $1.51B-21.2% | $1.92B | — |
| Net Income | $18.26B+6.6% | $17.13B+4444.6% | $377.0M-97.4% | $14.53B | — |
| Less: Net Income Attributable to Noncontrolling Interests | $9.0M-43.8% | $16.0M+33.3% | $12.0M+71.4% | $7.0M-46.2% | $13.0M |
| Net Income Attributable to Merck & Co., Inc. | $18.25B+6.6% | $17.12B+4589.6% | $365.0M-97.5% | $14.52B+11.3% | $13.05B |
| Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | $7.3M+8.0% | $6.8M+4728.6% | $140K-97.6% | $5.7M | — |
| Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | $7.3M+8.0% | $6.7M+4714.3% | $140K-97.5% | $5.7M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Merck: All The Focus On The Pipeline
Does Merck’s Upgraded 2026 Outlook And New HIV Approval Reshape The Bull Case For MRK?
MRK Q1 Deep Dive: Oncology Strength, New Launches, and Pipeline Milestones Define Quarter
Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard